Medicare Enrolled
Dr. Sudarsan Kollimuttathuillam, MD
Hematology & Oncology · Irvine, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kollimuttathuillam from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kollimuttathuillam?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kollimuttathuillam
Dr. Sudarsan Kollimuttathuillam is a hematology & oncology specialist in Irvine, CA, with 8 years of NPI registration. Based on federal Medicare data, Dr. Kollimuttathuillam performed 67,099 Medicare services across 1,414 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kollimuttathuillam received a total of $4,037 from 41 pharmaceutical and/or device companies across 163 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kollimuttathuillam is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 8 years in practice
▲ Top 11% volume in CA
$4,037 industry payments
Medicare Practice Summary
Medicare Utilization ↗67,099
Medicare services
Top 11% in CA for hematology & oncology
1,414
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~8,387 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
21,000 | $1 | $4 |
| Pembrolizumab injection (Keytruda) | 10,400 | $44 | $194 |
| Vedolizumab infusion (Entyvio) This procedure involves the administration of vedolizumab via injection. The dosage is measured in milligrams. |
8,700 | $17 | $77 |
| Anti-nausea injection (aprepitant) | 6,890 | $1 | $6 |
| Denosumab injection (Prolia/Xgeva) | 5,040 | $18 | $82 |
| Romosozumab injection (Evenity) for osteoporosis | 3,780 | $8 | $36 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
2,875 | $34 | $151 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
1,784 | $35 | $158 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
1,430 | $26 | $118 |
| Anti-nausea injection (ondansetron/Zofran) | 1,240 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
966 | $0 | $0 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
348 | $14 | $93 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
302 | $104 | $481 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
298 | $58 | $269 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
267 | $12 | $81 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
241 | $121 | $606 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
171 | $18 | $88 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
137 | $6 | $32 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
113 | $25 | $134 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
111 | $72 | $341 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
89 | $11 | $69 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
87 | $145 | $672 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
87 | $1 | $4 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
81 | $66 | $289 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
77 | $29 | $220 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
69 | $26 | $147 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
69 | $1 | $24 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
65 | $2 | $9 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
60 | $24 | $109 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
59 | $1 | $6 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
56 | $59 | $295 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
53 | $30 | $134 |
| New patient office visit, complex (60-74 min) | 30 | $188 | $821 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
22 | $100 | $434 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
21 | $109 | $474 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
18 | $138 | $623 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
17 | $34 | $200 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 16 | $14 | $62 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
15 | $22 | $103 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
15 | $70 | $306 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
54.8% high complexity
43.8% medium
1.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,037
Total received (2018-2024)
Avg $577/year across 7 years
Top 47% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
41
Companies
163
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,726 (92.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$311 (7.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,234
2023
$188
2022
$18
2021
$1,394
2020
$433
2019
$399
2018
$371
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$427
Celgene Corporation
$235
Astellas Pharma US Inc
$141
Menarini Silicon Biosystems, Inc.
$102
Takeda Pharmaceuticals U.S.A., Inc.
$86
Daiichi Sankyo Inc.
$83
GENZYME CORPORATION
$79
Merck Sharp & Dohme LLC
$46
Exelixis Inc.
$34
Top 3 companies account for 65.1% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$878
Celgene Corporation
$305
Amgen Inc.
$212
Astellas Pharma US Inc
$206
PFIZER INC.
$191
Merck Sharp & Dohme Corporation
$172
Pharmacyclics LLC, An AbbVie Company
$154
Takeda Pharmaceuticals U.S.A., Inc.
$136
E.R. Squibb & Sons, L.L.C.
$135
AstraZeneca Pharmaceuticals LP
$125
Boehringer Ingelheim Pharmaceuticals, Inc.
$120
Karyopharm Therapeutics Inc.
$108
Menarini Silicon Biosystems, Inc.
$102
Incyte Corporation
$98
Exelixis Inc.
$96
GENZYME CORPORATION
$93
Lilly USA, LLC
$84
Kite Pharma, Inc.
$84
Daiichi Sankyo Inc.
$83
Alexion Pharmaceuticals, Inc.
$77
Seagen Inc.
$72
Genentech USA, Inc.
$53
Bayer HealthCare Pharmaceuticals Inc.
$48
Merck Sharp & Dohme LLC
$46
EMD Serono, Inc.
$43
Eisai Inc.
$34
Regeneron Healthcare Solutions, Inc.
$30
Janssen Pharmaceuticals, Inc
$27
MorphoSys, US Inc.
$24
GlaxoSmithKline, LLC.
$24
Aurobindo Pharma USA, Inc.
$21
Servier Pharmaceuticals LLC
$20
Blueprint Medicines Corporation
$19
Foundation Medicine, Inc.
$17
Epizyme, Inc.,
$16
Myovant Sciences Inc.
$15
Jazz Pharmaceuticals Inc.
$14
Partner Therapeutics, Inc.
$14
Alnylam Pharmaceuticals Inc.
$14
Novartis Pharmaceuticals Corporation
$13
Novo Nordisk Inc
$11
Top 3 companies account for 34.6% of all-time payments
Associated products mentioned in payments ›
Avastin · BOSULIF · Beleodaq · CABOMETYX · CHANTIX · CYRAMZA · Cellsearch · DARZALEX · ELIQUIS · ERLEADA · EVENITY · Enhertu · FRUZAQLA · GAVRETO · GILOTRIF · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LORBRENA · LYNPARZA · Lenvima · Leukine · MONJUVI · NINLARO · Nplate · ONPATTRO · ONUREG · OPDIVO · ORGOVYX · PADCEV · Perjeta · REBINYN · REBLOZYL · Revlimid · SARCLISA · SOLIRIS · Stivarga · TAGRISSO · TALVEY · TAZVERIK · TECENTRIQ · TIBSOVO · VERZENIO · VYXEOS · XARELTO · XPOVIO · XTANDI · Xospata · Yescarta · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (92%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
150
Per 100K population
4.7
County median income
$113,702
Nearest hospital
HOAG ORTHOPEDIC INSTITUTE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kollimuttathuillam is a mixed practice specialist, with above-average Medicare volume (top 11% in CA), with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kollimuttathuillam experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Kollimuttathuillam performed 21,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kollimuttathuillam receive payments from pharmaceutical companies?
Yes. Dr. Kollimuttathuillam received a total of $4,037 from 41 companies across 163 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kollimuttathuillam's costs compare to other hematology & oncology specialists in Irvine?
Dr. Kollimuttathuillam's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kollimuttathuillam) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Irvine
Browse hematology & oncology specialists in Irvine ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology